Clinical Trial

Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-18; most recent amendment 2026-04-25.
Trial Details
NCT Number NCT07041203
Lead Sponsor Kristina Simonyan
Conditions Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor
Enrollment 8 participants
Start Date 2026-10-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-28